ViQi and Agilent sign a co-marketing agreement to promote AI-based automated imaging assays
Summary
Through ViQi and Agilents shared values in finding the best solutions for the labs we serve, we realize strong alignment in bringing reliable automated imaging assays to the market." The agreement will initially focus on organizations working with vaccines and antiviral research, with an emphasis on AVIA utilizing images from any of the Cytation instruments. • Quantification of Viral Infections Using AI/ML Analysis with Brightfield Imaging – A rapid viral infectivity assay using AVIA™ and the Agilent BioTek Cytation cell imaging multimode reader dramatically accelerates results, reduces costs, and increases precision [App Note on ViQis website] ViQi, a pioneering California-based image analysis company, unlocks the power of artificial intelligence (AI) and cloud-based software through the development of novel solutions that automate cell and tissue-based assays, transforming subjective analysis into objective, quantifiable results. We empower laboratories by making image processing and data management not only accessible but also efficient, ultimately accelerating breakthroughs in critical areas like virology research, drug discovery, and gene therapy. This translates into a faster and more accurate assessment of viral activity, leading to significant advancements in vaccine development and infectious disease research.